ADARx Prices Upsized $446M IPO at $17/Share with AbbVie $89M Private Placement
ADRX is trading near its 52-week low of $19 (3.8% below the low).
Summary
ADARx Pharmaceuticals priced its upsized IPO at $17.00 per share, raising $446 million, with AbbVie taking a concurrent $89 million private placement. Net proceeds of ~$495 million fund operations into 2030.
Updates
· GlobeNewswire — Underwriters fully exercised their option to buy 3,937,500 additional shares at $17.00, bringing total IPO shares to 30,187,500 and gross proceeds to $513.2 million.
· SEC 8-K — IPO and private placement closed on September 28, 2026; AbbVie purchased 5,255,542 shares for $89.3 million.
Key Events · Financing and Capital Events · ADRX
-
Upsized IPO Priced at $17.00/Share
26,250,000 shares offered at $17.00 per share for gross proceeds of $446.25 million. Underwriting discounts of $1.19 per share leave net proceeds to the company of $415.0 million before expenses.
-
AbbVie Concurrent Private Placement
AbbVie Inc. agreed to purchase 5,233,264 shares at $17.00 per share (~$89.0 million), capped at $100.0 million, resulting in AbbVie owning approximately 4.9% of outstanding shares post-offering. The placement is contingent on the IPO closing.
-
Underwriters' Option for Additional Shares
Underwriters have a 30-day option to purchase up to 3,937,500 additional shares at the IPO price less underwriting discounts, which would raise total gross proceeds to approximately $513 million.
-
Cash Runway Extended into 2030
Combined net proceeds of approximately $495.3 million (or $557.5 million with full option exercise) plus existing cash of $427.3 million as of June 30, 2026, are expected to fund operations into 2030.
Analysis · ADRX · Life Sciences
ADARx Pharmaceuticals finalized its upsized initial public offering, pricing 26.25 million shares at $17.00 per share for gross proceeds of $446.25 million. The deal includes a concurrent $89 million private placement with AbbVie Inc., which will own approximately 4.9% of the company post-offering. Net proceeds of roughly $495 million extend the cash runway into 2030, funding three clinical-stage siRNA programs and two preclinical candidates. The offering is dilutive to existing holders — new investors pay $17.00 per share against a pro forma as-adjusted net tangible book value of $5.64 per share, an immediate dilution of $11.36 per share. The stock is trading near its 52-week low of $19.00, and the IPO price sits below that level, reflecting a challenging market for biotech listings despite the upsized deal size.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1059 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADRX was trading at $18.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $19.00 to $23.21. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.